logo
Longtime advocate warns of Ohio deaths if federal HIV funding is cut

Longtime advocate warns of Ohio deaths if federal HIV funding is cut

Yahoo27-03-2025

COLUMBUS, Ohio (WCMH) — An Ohio HIV advocate said possible Trump administration plans to dial back HIV funding, including changes to a grant providing medication to low-income people with the virus, could cause thousands of deaths.
Gil Kudrin, a long-term HIV survivor, is speaking out following growing concern the Ryan White HIV/AIDS program, which delegates treatment grants for low-income patients, could be the next target of budget cuts. The program provides medication to more than 50% of those living with HIV in the U.S., about half a million people, according to the Health Resources and Services Administration.
'There are thousands of people in this county, in this city who rely on Ryan White for their very survival,' Kudrin said at the inaugural 'State of the LGBTQ+ Community' meeting in Cleveland in late February. 'If there is a 90-day interruption for that medication funding, it is likely in the following year there will be 109,000 deaths attributed to that interruption of treatment.'
Ohio group asks U.S. Supreme Court to allow student opt-outs for LGBTQ+ lessons
Kudrin's warning came after some Cleveland-area physicians told him they received memorandums detailing the end of the program's funding. Since then, the Trump administration has terminated other grants related to the HIV drug PrEP and begun weighing a dueling plan to eliminate the Centers for Disease Control and Prevention's division focused on HIV prevention, according to NBC News.
Under this plan, the CDC's HIV prevention work could transition to be under the Ryan White program, should it remain. However, LGBTQ+ advocates warn the move could easily overburden the program given it's designed to assist those living with HIV, not to promote prevention.
'The Ryan White HIV/AIDS Program does not fill all the HIV gaps,' Harold Phillips, deputy director for programs at the National HIV/AIDS Advocacy Network, told NBC News. 'It only serves those with an HIV diagnosis.'
Another potential plan would cut as much as $700 million for the CDC's HIV division, NBC News also found. Each option is in the preliminary stages, and no final decisions have been made yet.
The uncertainty surrounding the administration's HIV funding plan is why Kudrin is calling on Ohio's LGBTQ+ community to revive 'Act Up,' a protest movement that called for government action during the AIDS epidemic in the late '80s and early '90s. Kudrin, who has lived with HIV for around 40 years, said he has lost more than 100 friends to HIV and AIDS.
Olentangy schools defends LGBTQ+ anti-bullying policies in federal court
'I need you now to fight as desperately for my life as I fought for other people's lives because, if they take my meds away, I have 45 days left of Biktarvy,' said Kudrin, referring to a common HIV drug that can cost more than $4,000 for a month-long supply. 'When you take my meds away, I will die. I will die within a year, at most, two. And I have a lot to live for.'
Kurdin's plea is especially poignant in a state like Ohio, which is home to six laws that have yielded at least 214 HIV-related criminal prosecutions from 2014 to 2020. While Statehouse proposals to repeal or alter those laws have been unsuccessful, Kurdin encouraged community members to continue advocating for the 27,000 Ohioans living with HIV.
'This is not a joke, this is a call to action,' Kudrin said. 'If you do not act up now, you will never have another chance.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump's former Commerce Secretary, Wilbur Ross, says the US-China deal is still far from comprehensive
Trump's former Commerce Secretary, Wilbur Ross, says the US-China deal is still far from comprehensive

Business Insider

time9 minutes ago

  • Business Insider

Trump's former Commerce Secretary, Wilbur Ross, says the US-China deal is still far from comprehensive

President Donald Trump's former Secretary of Commerce doesn't think the trade deal between the US and China is close to being "done." "It looks as though they made a fairly modest deal, mostly focusing on export controls on both the US side and the China side," Wilbur Ross, who was part of the first Trump administration, told Business Insider. "So it's far from a comprehensive deal." On Wednesday morning, Trump said on Truth Social that the deal with China is now "done." "It seems more or less to be reiterating the deal they thought they had set a few weeks ago," Ross said of the deal. China and the US reached a trade framework agreement on Tuesday, after their respective negotiation teams held two-day talks in London. The current Secretary of Commerce, Howard Lutnick, is part of the US trade talk team. "Full magnets, and any necessary rare earths, will be supplied, up front, by China," Trump added in all caps in the post. "Likewise, we will provide to China what was agreed to, including Chinese students using our colleges and universities (which has always been good with me!)." Ross said that the deal has not addressed many important issues, including intellectual property, so it may be too soon to call this a victory. "The Chinese side has been very careful to say it still needs to be approved by President Xi," said Ross. "When we negotiated with the China side last time, it wasn't unusual for the trade negotiators to agree to something, and then they would go back to Xi, and he would not go along with it." This year in duties on imports from China reached up to 245% on some goods. On May 14, many of the tariffs on China were reduced to 30% for 90 days, with a deadline of August 12. A 10% baseline tariff is still in place on the rest of the world, while additional higher tariffs on 75 countries have been paused until July 9. Ross said that it would be important to complete at least a few deals with key trading partners before the tariff pause on 75 countries expires. "I think that will help clear the air for the stock market because it'll start to show a direction and that there is a way to get all these things resolved," he said. "It's very important from a bond market point of view and from an equity market point of view."

Trump Treasury Secretary Suddenly Backtracks on Major Tariff Deadline
Trump Treasury Secretary Suddenly Backtracks on Major Tariff Deadline

Yahoo

time11 minutes ago

  • Yahoo

Trump Treasury Secretary Suddenly Backtracks on Major Tariff Deadline

Treasury Secretary Scott Bessent indicated that Donald Trump is again intending to move the goalposts for his global tariff policy. The United States is fast approaching the end of the president's 90-day pause on his sweeping global tariffs on July 9, but while testifying before the House Ways and Means Committee on Wednesday, Bessent said that 'Liberation Day' Part 2 may not come to pass so soon. 'I would say, as I have repeatedly said, that there are 18 important trading partners. We are working toward deals on those. And it is highly likely that those countries that are negoti—or trading blocs, in the case of the EU—who are negotiating in good faith, we will roll the date forward to continue good-faith negotiations,' Bessent said. 'If someone is not negotiating, then we will not,' he added. The Trump administration has not even vaguely approached its initial promise to crack 90 deals in 90 days, only announcing two unfinished deals, with the U.K. and China. Crucially, Trump's paltry set of terms with China isn't even a deal. China referred to it as merely a 'framework,' while Commerce Secretary Howard Lutnick said it was a 'handshake for a framework' that both Trump and Chinese President Xi Jinping need to approve. Trump seems intent on running the country's economic policy in 90-day increments, prolonging economic uncertainty that has roiled the markets and sent prices rising. But the president's failure should hardly come as a surprise, as the stated purpose of his tariffs—not to ensure economic prosperity but to bring U.S. trading partners to their knees—defies all logic and reason. With only two half-deals made, and a suddenly unclear horizon, it's not clear how TACO Trump will ever reach the goal of 200 trade deals he'd claimed to have made in April. Especially considering that there aren't even that many countries.

Kennedy names new members of CDC vaccine advisory panel days after removing previous advisers
Kennedy names new members of CDC vaccine advisory panel days after removing previous advisers

CNN

time22 minutes ago

  • CNN

Kennedy names new members of CDC vaccine advisory panel days after removing previous advisers

Just two days after retiring the entirety of the US Centers for Disease Control and Prevention's vaccine advisory panel, US Health and Human Services Secretary Robert F. Kennedy Jr. has appointed several prominent critics of the government's Covid-19 response to that committee. He announced eight new members of the CDC's Advisory Committee on Immunization Practices, or ACIP, on Wednesday. Kennedy had said Monday that the previous 17-member panel that makes recommendations on who should get vaccines and when was rife with conflicts of interest and that he would appoint new 'highly credentialed' experts in time for the panel's June 25 meeting, at which the members are expected to discuss guidance for Covid-19 and HPV shots, among others. In a statement Wednesday, Kennedy said the reassembled panel will demand 'definitive safety and efficacy data before making any new vaccine recommendations, but will also review data for the current vaccine schedule as well.' The eight new ACIP members include Dr. Robert Malone, a biochemist who made early innovations in the field of messenger RNA but in more recent years has been a vocal critic of mRNA technology in Covid-19 vaccines. The CDC recently narrowed its recommendations for mRNA Covid-19 shots, but some advocates in the Make America Healthy Again space have pressed Kennedy to go further and bar the vaccines entirely. Another new member is Dr. Martin Kulldorff, a biostatistician and epidemiologist who co-authored an October 2020 strategy on herd immunity known as the Great Barrington Declaration with Dr. Jay Bhattacharya, now director of the US National Institutes of Health. Both Malone's and Kulldorff's names were circulated early in the second Trump administration as potential advisers on ACIP or other panels, according to a person familiar with the process who requested anonymity because they weren't authorized to speak with CNN. Kennedy also chose Dr. James Pagano, an emergency medicine physician he described as a 'strong advocate for evidence-based medicine' who has served on hospital committees and medical executive boards. Dr. Retsef Levi, an MIT professor who has published studies on mRNA vaccines and cardiovascular events, is also joining the panel. Levi is a professor of operations management. Several of the new members have served in federal health agencies previously, including Dr. Joseph Hibbeln, a former acting chief of the NIH's section on nutritional neurosciences. Dr. Cody Meissner, a Dartmouth professor of pediatrics who also signed the Great Barrington Declaration, has previously served on ACIP and on the US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee. Dr. Vicky Pebsworth, the Pacific region director of the National Association of Catholic Nurses, also served on the FDA committee and on a national panel reviewing the 2009 H1N1 swine flu vaccine. Dr. Michael Ross, a professor of obstetrics and gynecology at George Washington University and Virginia Commonwealth University, has previously served on the CDC's Advisory Committee for the Prevention of Breast and Cervical Cancer. Kennedy also nodded in his statement to Ross' 'continued service on biotech and healthcare boards.' The private equity company Havencrest, in which Ross is an operating partner, describes him on its site as a 'serial CEO' who has served on the boards of several biotechnology companies.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store